New combo therapy shows promise for tough-to-treat pancreatic cancer
NCT ID NCT03983057
First seen Feb 11, 2026 · Last updated May 01, 2026 · Updated 16 times
Summary
This study tested whether adding an immunotherapy drug (anti-PD-1 antibody) to standard chemotherapy can help people with locally advanced or borderline resectable pancreatic cancer. The trial involved 392 participants and compared the combination treatment to chemotherapy alone. The goal was to see if the combo could delay cancer growth, improve survival, or shrink tumors enough for surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.